Metformin may be ‘plausible target’ for dry AMD target, study finds
A population-based study found an increased incidence of metformin use in patients without age-related macular degeneration (AMD) compared to patients with dry AMD, suggesting it may be a potential target for use in the treatment of AMD.
This retrospective review included 3 age- and sex-matched cohorts including patients with exudative AMD (n = 504), a cohort of dry AMD patients (n = 504), and a cohort of patients without AMD (n = 504). The prevalence of diabetes between cohorts was similar.
Patients with no AMD had an increased likelihood of metformin use compared to patients with dry AMD (p = 0.0168, OR 1.66 (1.09-2.51).
No difference in the likelihood of metformin use between exudative AMD patients and non-AMD controls was found.
Starr MR, Dalvin LA, AbouChehade JE, et al. Incidence of metformin use in patients with age-related macular degeneration versus normal controls: A population-based study in Olmsted County, Minnesota. Eye (Lond). 2022 Sep 23. doi: 10.1038/s41433-022-02245-6. Epub ahead of print. PMID: 36151313.